<DOC>
	<DOCNO>NCT01201811</DOCNO>
	<brief_summary>The primary purpose study determine effectiveness safety azacitidine treatment Taiwanese subject higher-risk Myelodysplastic Syndrome ( MDS ) .</brief_summary>
	<brief_title>Study Azacitidine Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes ( MDS )</brief_title>
	<detailed_description>The study 3 phase include Screening Phase , Treatment Phase , Post-Treatment Phase outline follow : Screening Phase : Subjects provide inform consent prior undergoing study-related procedure . Screening procedure take place within 28 day prior initiation azacitidine treatment ( Day 1 , Cycle 1 ) . Subject eligibility base central pathology review . Bone marrow aspirate bone marrow biopsy collect screen send morphological assessment central pathology reviewer prior subject receive IP . The central pathology reviewer document MDS classification accord FAB WHO criteria ( Appendix A B , respectively ) . A standard cytogenetic metaphase preparation prepare bone marrow aspirate send local central laboratory ( site without local analysis capability ) cytogenetic analysis prior receive IP . The IPSS score calculate use central reviewer 's pathology report bone marrow blast percentage , local cytogenetic assessment karyotype , central laboratory report number cytopenia ( Appendix D ) . Treatment Phase : The first dose azacitidine subject begin Day 1 Cycle 1 . All subject receive azacitidine 75 mg/m2/day SC 7 day every 28 day 6 cycle , unless discontinue treatment . Visits treatment phase schedule weekly first 2 cycle , every week subsequent cycle throughout rest study . Safety efficacy measure perform weekly , every week , every 4 week , 24 week , depend procedure . Post-Treatment Phase : All discontinue subject , regardless reason discontinuation , undergo end-of-study procedure time study discontinuation . Subjects follow-up visit collection adverse event 28 day last IP dose .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Antimetabolites , Antineoplastic</mesh_term>
	<mesh_term>Antimetabolites</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>A diagnosis RAEB RAEBT accord FAB classification MDS IPSS score intermediate2 high risk diagnosis myelodysplastic CMML per modify FAB criterion . Taiwanese male female â‰¥ 18 year age ECOG 0 , 1 , 2 ; Adequate hepatic renal organ function Previous treatment azacitidine decitabine Malignant disease diagnose within prior 12 month Uncorrected red cell folate deficiency vitamin B12 deficiency Diagnosis metastatic disease Malignant hepatic tumor Known suspected hypersensitivity azacitidine mannitol Prior transplantation cytotoxic therapy , include azacitidine chemotherapy , administer treat MDS Treatment erythropoietin myeloid growth factor 21 day prior Day 1 Cycle 1 androgenic hormone 14 day prior Day 1 Cycle 1 ; Active HIV viral hepatitis type B C Treatment investigational drug within previous 30 day prior Day 1 Cycle 1 , ongoing adverse event previous treatment investigational drug , regardless time period ; Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Taiwan</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>Vidaza</keyword>
	<keyword>Celgene</keyword>
	<keyword>Pathologic Processes</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Bone Marrow Diseases</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Antimetabolites , Antineoplastic</keyword>
	<keyword>Antimetabolites</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Enzyme inhibitor</keyword>
</DOC>